FADS Genes and Omega-3 Conversion: Optimizing Your Essential Fatty Acid Status

Not everyone who eats the same amount of fish and flaxseed ends up with the same omega-3 levels. Behind this variability lies a set of genes, the FADS gene cluster, that control how efficiently your body converts plant-based omega-3s into the long-chain fatty acids EPA and DHA that your brain, heart, and immune system actually need.

Understanding your FADS genetic profile could fundamentally change how you approach omega-3 nutrition, and whether you need to prioritise fish, algae oil, or simply eat more flaxseed.

The Three Omega-3s You Need to Know

Omega-3 fatty acids come in three main dietary forms, and they are not interchangeable:

• ALA (alpha-linolenic acid): The plant-based form, found in flaxseed, chia seeds, walnuts, and rapeseed oil. ALA is essential, meaning the body cannot make it, but it's biologically inactive until converted.
• EPA (eicosapentaenoic acid): The anti-inflammatory long-chain omega-3, primarily found in oily fish and marine algae. Directly supports cardiovascular health, reduces inflammatory markers, and influences mood.
• DHA (docosahexaenoic acid): The structural omega-3, making up approximately 30-40% of the brain's cortex and retina. Critical for cognitive function, foetal brain development, and visual acuity.

EPA and DHA are the forms your body uses. The question is: can you make them from ALA, or do you need to obtain them directly from food?

The FADS Gene Cluster: Your Conversion Capacity

The FADS1 and FADS2 genes encode the enzymes delta-5 desaturase and delta-6 desaturase, respectively. These enzymes catalyse the elongation and desaturation steps that convert ALA → EPA → DHA in a sequential, multi-step process.

The efficiency of this conversion pathway is substantially determined by which variants of FADS1 and FADS2 you carry:

High-Activity FADS Variants (rs174537, rs174575, Major Alleles)

People carrying higher-activity variants of the FADS genes convert ALA to EPA and DHA relatively efficiently. Research suggests conversion rates of approximately 5-8% for EPA and 0.5-1% for DHA from ALA. While still limited, these individuals can derive some meaningful EPA/DHA from plant sources, and their blood fatty acid profiles tend to respond more robustly to increased ALA intake.

Low-Activity FADS Variants (Minor Alleles)

Individuals with lower-activity variants show dramatically reduced desaturase activity, conversion rates can fall to 0.1-0.5% or less for DHA from ALA. For these individuals, plant-based omega-3 foods provide virtually no usable EPA or DHA. They are entirely dependent on preformed EPA/DHA from marine sources or supplements.

Studies in vegetarian and vegan populations show that FADS genotype is the single strongest predictor of circulating EPA and DHA levels, more powerful than dietary intake alone. Two vegans eating identical diets can have EPA/DHA levels that differ by 300-400%.

Why This Matters More Than You Think

Inflammation and Immune Function

EPA is a direct precursor to anti-inflammatory eicosanoids, prostaglandins, thromboxanes, and leukotrienes, that regulate inflammation throughout the body. Low EPA status is consistently associated with elevated inflammatory markers including CRP, IL-6, and TNF-alpha. For individuals with low-activity FADS variants who rely on plant-based diets, achieving adequate EPA without direct supplementation is virtually impossible.

Brain Health and Cognition

DHA is not merely beneficial for brain health, it is structurally essential. The brain preferentially accumulates DHA throughout life, with the highest demands occurring during foetal development and early infancy. Low DHA status has been associated with accelerated cognitive decline, depression, and ADHD. Critically, the brain cannot synthesise DHA and depends entirely on dietary supply.

Pregnancy and Infant Development

The demands for DHA spike dramatically during pregnancy. Foetal DHA accretion during the third trimester is approximately 50-70mg/day. Maternal FADS status is a significant determinant of placental DHA transfer. Women with low-activity FADS variants who are plant-based face a particularly high risk of DHA depletion during pregnancy.

Cardiovascular Health

EPA and DHA reduce triglycerides, lower blood pressure modestly, improve arterial compliance, and reduce platelet aggregation. Meta-analyses of randomised controlled trials show consistent cardiovascular benefit, particularly for triglyceride reduction (up to 30% at doses of 2-4g/day).

Best Food Sources of Preformed EPA and DHA

Regardless of FADS genotype, these foods provide the most reliable EPA and DHA:

Fatty Fish (Highest Sources)

• Sardines (canned in water): ~2,200 mg EPA+DHA per 100g, one of the most economical and sustainable sources
• Mackerel: ~2,500 mg EPA+DHA per 100g
• Atlantic salmon (farmed): ~2,150 mg EPA+DHA per 100g
• Anchovies: ~1,500 mg per 100g, excellent in small amounts
• Herring: ~1,700 mg per 100g
• Fresh tuna: ~1,100 mg per 100g (canned light tuna is lower, ~200mg)

The Plant-Based Alternative: Algae Oil

Marine algae, not fish, are the primary producers of EPA and DHA in the ocean. Fish are omega-3-rich because they eat algae (directly or through the food chain). Algal oil supplements provide preformed DHA and EPA directly, bypassing FADS conversion entirely. This makes algal oil equally effective for individuals with low-activity FADS variants as fish oil, while being entirely plant-derived.

ALA Sources (Valuable but Insufficient Alone for Low-Activity FADS)

• Ground flaxseed: 2,350 mg ALA per tablespoon
• Chia seeds: 5,050 mg ALA per 28g serving
• Walnuts: 2,570 mg ALA per 28g serving
• Hemp seeds: 2,500 mg ALA per 28g serving

Optimising Your Omega-6 to Omega-3 Ratio

FADS genotype also influences how your body handles omega-6 fatty acids, particularly linoleic acid (LA). The same FADS enzymes convert both omega-6 and omega-3 precursors, and they compete for enzyme binding. Diets very high in omega-6 (from refined vegetable oils like sunflower, corn, and soybean oil) can impair omega-3 conversion even in those with high-activity FADS variants.

The evolutionary human omega-6:omega-3 ratio was approximately 4:1. Modern Western diets typically range from 15:1 to 20:1. Reducing omega-6 intake while increasing omega-3 sources is beneficial regardless of genotype, but particularly important for those with low-activity FADS variants.

Supplement Dosing by FADS Profile

• High-activity FADS, omnivore: 2 portions oily fish per week may be sufficient. Consider 250-500mg EPA+DHA supplement if fish intake is low.
• High-activity FADS, plant-based: Algae oil 250-500 mg DHA+EPA/day, plus generous ALA sources.
• Low-activity FADS, omnivore: 2-3 portions oily fish per week; supplement with 500-1000mg EPA+DHA on non-fish days.
• Low-activity FADS, plant-based: Algae oil minimum 500-1000 mg DHA+EPA/day. ALA sources alone are insufficient, preformed DHA/EPA is essential.

Key Takeaways

• The FADS1 and FADS2 genes control the conversion of plant ALA into long-chain EPA and DHA, with up to 10-fold differences between individuals
• Low-activity FADS variants are particularly common and mean plant sources provide virtually no usable DHA
• Algae oil delivers preformed DHA/EPA and is equally effective to fish oil, making it ideal for plant-based individuals with low FADS activity
• Reducing omega-6 intake (refined seed oils) improves omega-3 status by reducing competition for FADS enzymes
• DHA is a structural component of the brain, there is no adequate substitute, and status should be monitored especially during pregnancy

Scientific References

Key research informing this article includes work by Sergeant et al. (2016) on FADS polymorphisms and fatty acid status, Plourde & Cunnane (2007) on ALA conversion rates, and the landmark GISSI-Prevenzione trial on omega-3 and cardiovascular outcomes. Data on algae oil bioequivalence to fish oil is supported by multiple randomised crossover studies.